PASS Assisted Prediction and Meta-analysis of Active Phytoconstituents of <i>Guggul</i> for the Treatment of Chronic Prostatitis: A Gateway to Cure Prostate Cancer

Background: Mostly men are particularly prone to prostate cancer as well as chronic prostatitis the underlying causes behind prostate cancer as well as chronic prostatitis are multifaceted as well as diverse a spike in serum prostate-specific antigen characterises both diseases. Chronic prostatitis is prostate inflammation independent of the source inflammation and is linked to a variety of malignancies in general along with prostate inflammatory reactions that are thought to have a contributing influence on the advancement and growth of prostate cancer. Aim: This study aims to identify different phytoconstituents of Guggulu for treating chronic prostatitis along with meta-analysis. Meta-analysis is used as an analytical technique to aggregate results of separate inferential statistics investigations of clinical data on chronic prostatitis. Methods: Phytochemical ingredients were analyzed using PASS estimates. Canonical SMILES were identified to determine Pa values. PASS software was then used to forecast activities. Doxycycline, a conventional drug for chronic prostatitis, was selected for comparison. Data was collected using the PASS online program to estimate physiological and biochemical parameters. The activities of all constituents were then compared against doxycycline. Results: The results indicate that Guggul sterone Z shows promise as a candidate for further investigation in medication therapy for chronic prostatitis. A meta-analysis aims to identify clinical trials for this phytoconstituent, which has yielded the highest number of results. PASS prediction findings reveal that Guggul sterone Z, followed by Mansumbinone, 16-dehydroprogesterone, and alpha-pinene, exhibit the most significant activities. Conclusion: The study forecasted that Guggul sterone Z, Mansumbinone, 16-dehydroprogesterone and alpha-pinene are the potential phytoconstituents that can play a vital role in the development of novel treatments for chronic prostatitis-induced prostate cancer.